Opendata, web and dolomites

PulseHaler

PulseHaler: Improving the Lives of COPD Patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PulseHaler project word cloud

Explore the words cloud of the PulseHaler project. It provides you a very rough idea of what is the project "PulseHaler" about.

mouth    entire    goes    adults    history    difficulty    patients    debilitating    pollution    improvements    efficiency    functional    unprecedented    al    capacity    respiratory    pulmonary    cough    index    et    copd    obstructive    270    bronchitis    demonstrated    cigarette    city    feeling    reduce    enhancement    die    emphysema    collapse    small    penetration    group    progressive    10    effect       walk    exposure    disease    massive    airflow    halbert    6mw    world    core    airways    alveolar    stomach    size    tests    medical    invasive    chronic    dyspnoea    clinical    respinova    cooking    care    time    smoking    safety    approximately    treat    fold    equivalent    bronchioles    minute    airway    fuels    biomass    trade    source    zone    pharmaceutical    annually    pollutants    validated    efficacy    named    ed    functions    drug    countries    inhaled    first    kills    2003    people    drugs    venice    dramatically    terminal    million    spirometry    amount    breathing    device    markedly    pulsehaler    air    pathophysiology    lung    successfully    standard    limitations   

Project "PulseHaler" data sheet

The following table provides information about the project.

Coordinator
RESPINOVA LTD 

Organization address
address: 8 HACHOSHLIM ST.
city: HERZLIYA PITUACH
postcode: 4672408
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.respinova.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESPINOVA LTD IL (HERZLIYA PITUACH) coordinator 50˙000.00

Map

 Project objective

Chronic obstructive pulmonary disease (COPD) is a group of progressive, debilitating respiratory conditions, including emphysema and chronic bronchitis, characterized by difficulty breathing, lung airflow limitations, cough, and markedly reduced functional capacity. COPD often is associated with a history of cigarette smoking or exposure to pollutants. It kills approximately 270,000 people in the EU annually, equivalent to the size of the entire city of Venice. It affects 4% and 10% of adults in Europe (Halbert et al., 2003). World-wide 5-10% are affected and 3 million die each year (source: WHO). In the developing countries, COPD has been growing dramatically due to increased air pollution, smoking and massive use of biomass fuels for cooking. Respinova has developed a novel non-invasive technology and medical device named the PulseHaler™, that aims to treat the core of the COPD pathophysiology – small airway collapse. The technology was successfully validated in two clinical studies. In the first study, PulseHaler was evaluated for its ability to open small airways. Clinical results demonstrated unprecedented improvements in the 6 minute walk test (6MW), spirometry lung functions tests and in the feeling of dyspnoea. All of these effects were above and beyond the effect of standard pharmaceutical care. In the second study, PulseHaler™ was successfully used as a new means for improved delivery of inhaled drugs to the terminal bronchioles and the alveolar zone in COPD patients. It resulted in three-fold enhancement of penetration index, a measure of efficiency of drug delivery. By improving the drug delivery, PulseHaler technology can enhance efficacy & safety of drug delivery. It can reduce the amount of drug required, ensure less drug goes to non-lung areas (mouth, stomach etc.), and reduce time required to deliver the drugs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PULSEHALER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PULSEHALER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More